Holen Sie sich die Stockscreener-App
9.23
2.17%
-0.205
Handel nachbörslich:
9.23
Upstream Bio Inc Aktie (UPB) Neueste Nachrichten
Upstream Bio (NASDAQ:UPB) Trading 14.4% HigherShould You Buy? - MarketBeat
UPB: Phase II data support quarterly dosing for verekitug, with phase III and COPD programs advancing - TradingView
UPB: Verekitug's quarterly dosing shows robust efficacy, with phase 3 and COPD programs advancing - TradingView
Upstream Bio, Inc. CEO joins Leerink Partners fireside chat at global healthcare conference - Traders Union
Dip Buying: Is Upstream Bio Inc forming a breakout pattern2025 Stock Rankings & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Aug Sectors: Can Upstream Bio Inc deliver consistent dividendsJuly 2025 Outlook & Community Verified Watchlist Alerts - baoquankhu1.vn
Lifesci Capital Forecasts Upstream Bio Q2 Earnings - MarketBeat
Brokerages Set Upstream Bio, Inc. (NASDAQ:UPB) Price Target at $45.25 - Defense World
Why Did UPB Stock Plunge 40% Today? - Stocktwits
RSI Check: Can Upstream Bio Inc outperform in the next rallyWeekly Trade Summary & Weekly Chart Analysis and Guides - baoquankhu1.vn
UPB: Verekitug shows best-in-class efficacy and safety, advancing to phase 3 with quarterly dosing - TradingView
CEO Rand Sutherland hosts live conference fireside chat, Upstream Bio, Inc. asserts - Traders Union
Upstream Bio (UPB) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Upstream Bio presents additional Phase 2 data for verekitug - Investing.com South Africa
Upstream Bio presents additional Phase 2 data for verekitug By Investing.com - Investing.com Canada
Upstream Bio, Inc. unveils new analyses from VIBRANT Phase 2 trial at AAAAI2026 - Traders Union
Upstream Bio says primary endpoint showed reduction of -1.95 in nasal polyp score - marketscreener.com
Upstream Bio Says Primary Endpoint Showed Reduction of -1.95 in Nasal Polyp Score - TradingView
Upstream Bio Presents Additional Analyses from the Phase 2 - GlobeNewswire
Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting - Sahm
UPB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Upstream Bio, Inc. (UPB) Stock Analysis: Exploring a 505% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Upstream Bio to present verekitug CRSwNP trial data at AAAAI By Investing.com - Investing.com Australia
Upstream Bio to present verekitug CRSwNP trial data at AAAAI - Investing.com
Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026 - Bitget
UPB Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
UPBUpStream Bio Inc. Latest Stock News & Market Updates - Stock Titan
Upstream Bio to Participate in Investor Conferences in March 2026 - geneonline.com
Peering Into Upstream Bio Inc's Recent Short Interest - Benzinga
Upstream Bio announces participation in major healthcare conferences - Traders Union
Upstream Bio to Participate in Upcoming March Investor Conferences - GlobeNewswire
Insider Trends: Is Upstream Bio Inc a defensive stockTrade Entry Summary & Community Driven Trade Alerts - baoquankhu1.vn
Can Upstream Bio Inc. ride the EV waveJuly 2025 Rallies & Expert Approved Momentum Ideas - mfd.ru
What are the risks of holding Upstream Bio Inc.2025 Sector Review & Reliable Intraday Trade Plans - mfd.ru
Is Upstream Bio Inc. stock suitable for long term investing2025 Geopolitical Influence & Reliable Price Breakout Alerts - mfd.ru
Upstream Bio down despite mid-stage trial win for asthma drug - MSN
Upstream Bio crashes after asthma drug succeeds — with the wrong dose - MSN
S P Trends: Is Upstream Bio Inc forming a bullish divergenceJuly 2025 Gainers & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Upstream Bio Shares Phase II VALIANT Data: Verekitug Cuts Severe Asthma Exacerbations Up to 56% - Defense World
Companies Like Upstream Bio (NASDAQ:UPB) Are In A Position To Invest In Growth - Yahoo Finance
Can Upstream Bio Inc. stock reach $100 price targetJuly 2025 Institutional & Technical Buy Zone Confirmations - mfd.ru
Exit Recap: Is Upstream Bio Inc. still a buy after recent gainsJuly 2025 Breakouts & Weekly Return Optimization Alerts - mfd.ru
UPB Should I Buy - Intellectia AI
UPB PE Ratio & Valuation, Is UPB Overvalued - Intellectia AI
Growth Recap: Is CNMD stock heavily shortedWeekly Trading Summary & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Upstream Bio (NASDAQ:UPB) Sees Large Volume IncreaseHere's Why - MarketBeat
What is the next catalyst for Upstream Bio Inc.Quarterly Earnings Summary & Real-Time Volume Trigger Notifications - mfd.ru
Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns - Bitget
Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT), Tenet Healthcare (THC) and Upstream Bio, Inc. (UPB) - The Globe and Mail
Upstream Bio’s stock drops 47% on verekitug Phase II asthma data - Clinical Trials Arena
Upstream Bio (NASDAQ:UPB) Trading Down 10.3%Time to Sell? - MarketBeat
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):